Switch to:
GlaxoSmithKline PLC (NYSE:GSK)
Research and Development
$5,401 Mil (TTM As of Jun. 2015)

This is the expense the company spent on research and development. GlaxoSmithKline PLC's research and development for the three months ended in Jun. 2015 was $1,265 Mil. Its research and development for the trailing twelve months (TTM) ended in Jun. 2015 was $5,401 Mil.


Definition

This is the expense the company spent on research and development.

GlaxoSmithKline PLC Research & Development for the trailing twelve months (TTM) ended in Jun. 2015 was 1307.81758958 (Sep. 2014 ) + 1532.08137715 (Dec. 2014 ) + 1295.96412556 (Mar. 2015 ) + 1264.79750779 (Jun. 2015 ) = $5,401 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.


Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Related Terms

Gross Profit


Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.

GlaxoSmithKline PLC Annual Data

Dec05Dec06Dec07Dec08Dec09Dec10Dec11Dec12Dec13Dec14
Research & Development 5,4726,7906,5335,4706,6666,9536,2546,4106,4215,399

GlaxoSmithKline PLC Quarterly Data

Mar13Jun13Sep13Dec13Mar14Jun14Sep14Dec14Mar15Jun15
Research & Development 1,3631,6241,4311,7511,4271,3691,3081,5321,2961,265
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GuruFocus Premium Plus Membership

FEEDBACK